Home › Research › Treatments
Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease
Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R.. Movement disorders : official journal of the Movement Disorder Society, 2006-11-01
Topic: Risk, prevention and care in population studies
We aimed to determine prospectively whether rivastigmine, an inhibitor of acetylcholinesterase and butyrylcholinesterase, provided benefits in patients with and without visual hallucinations in a population with dementia associated with Parkinson's disease (PDD). This was a 24-week double-blind placebo-controlled study. Primary efficacy measures were the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) and Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change (ADCS-CGIC).
Key findings
- This was a 24-week double-blind placebo-controlled study.
- Primary efficacy measures were the Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-cog) and Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change (ADCS-CGIC).
- Secondary efficacy measures included activities of daily living, behavioral symptoms, and executive and attentional functions.
- Patients were stratified according to the presence of visual hallucinations at baseline.
Why it matters
This 24-week double-blind placebo-controlled study tested rivastigmine in patients with dementia associated with Parkinson's disease, including those with and without visual hallucinations. It evaluates a drug for Parkinson's disease dementia, not a cure or prevention for Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants188
- Evidence strengthLow
How this study scored 65/100
Published in a peer-reviewed journal, and it is a randomised controlled trial. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Movement disorders : official journal of the Movement Disorder Society) |
| Journal's citation record | 3 / 4 | Movement Disorders: journal h-index 281 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomised controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2006 — older than 20 years, still counted |
| Sample size | 2 / 4 | 188 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 2 / 2 | Randomised and blinded or placebo-controlled (as stated in the record) |
| Times cited | 6 / 7 | Cited 311 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 14.1 citations a year over 22 year(s) since 2006 |
| Impact for its field and year | 4 / 6 | Cited 10.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 11 other studies in this library |
| Still being cited | 2 / 4 | Cited 17 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Roger M. Lane: h-index 47 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Antwerp: institution h-index 834 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 5 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 16960863) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 65 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
APA 7th
Burn, D., Emre, M., McKeith, I., De Deyn, P. P., Aarsland, D., Hsu, C., et al. (2006). Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. https://doi.org/10.1002/mds.21077
Vancouver
Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2006. doi:10.1002/mds.21077. PMID: 16960863.
BibTeX
@article{burn2006-16960863,
author = {Burn, D. and Emre, M. and McKeith, I. and De Deyn, P. P. and Aarsland, D. and Hsu, C. and Lane, R.},
title = {{Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease}},
journal = {Movement disorders : official journal of the Movement Disorder Society},
year = {2006},
doi = {10.1002/mds.21077},
pmid = {16960863},
url = {https://doi.org/10.1002/mds.21077}
}
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.